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Abstract. The outbreak of Ebola virus disease (EVD) in West Africa has outstripped available resources. Novel
strategies are desperately needed to streamline operations. The present norm of requiring negative results on polymerase
chain reaction for EVD convalescent patients to be discharged is not evidence-based and often results in asymptomatic
patients competing for beds in dangerously crowded Ebola Treatment Units, posing risks to ward staff and patients and
the community if infected persons are turned away. We summarize the relevant data and call for a change in discharge
criteria for convalescent patients that can safely help reduce the strain on resources and direct energies where they are
most needed. In the longer term, research is needed to assess the true infectivity of EVD convalescent patients to establish
evidence-based criteria and guidelines for discharge.
The outbreak of Ebola virus disease (EVD) in West Africa
has been declared a public health emergency of interna-
tional concern by the World Health Organization (WHO),1
in large part because the scale of the outbreak has out-
stripped available resources.2,3 We believe that a change in
the discharge policy for convalescent patients can help reduce
the strain on resources and direct energies where they are
most needed.
In the last 15 years mobile laboratories have been routinely
installed in epidemic areas to perform diagnostic testing for
EVD by testing of blood by real-time polymerase chain reac-
tion (PCR). With the assay at hand, patient discharge criteria
of being asymptomatic for 3 days and testing PCR negative
has become the norm.4 In our experience providing patient
care at Ebola Treatment Units (ETUs) in Sierra Leone and
Guinea during this outbreak, the interval between a patient
becoming asymptomatic and testing PCR negative varies
widely. In many cases completely asymptomatic convalescent
patients wait days or even weeks to be released, either because
their PCR result remains positive, often at a very low level,
or simply because the laboratory is too over-run with samples
from suspected new cases to perform the assay on the conva-
lescents. Meanwhile, in many ETUs suspected cases are being
turned away because of a critical shortage of beds; we faced
this situation in the ETU at Kenema Government Hospital,
Sierra Leone, in July 2014, when ~25% of the official bed
capacity was occupied by asymptomatic but PCR-positive
patients, usually very impatient to go home. Wards became
dangerously overcrowded and increasingly hazardous for staff
and patients, deterring EVD cases from being admitted to the
Kenema ETU, creating a backlog of EVD-confirmed cases
in peripheral holding units, which necessitated diversion of
cases to the already over-crowded ETU run by Medicine Sans
Frontieres in neighboring Kailahun District.
In addition to the operational challenges caused, there is
little justification of the PCR-negative requirement on scien-
tific grounds. The viral load in EVD closely parallels the
clinical status5 and is thus logically very low in asymptomatic
persons. In contrast, symptomatic patients, particularly when
severely ill, have high viral loads and are very infectious,
posing a far greater community transmission threat.5,6 No
secondary transmission was noted in a study of 152 house-
hold contacts of 29 convalescent EVD patients followed for
up to 21 months after illness.7 All 481 specimens (85 tears,
84 sweat, 79 feces, 95 urine, 86 saliva, 8 semen, 44 vaginal
secretions) taken from the convalescent patients between
Days 12 and 157 after the onset of illness tested negative
by both PCR and cell culture, with the exception of a few
PCR-positive results from semen, consistent with the gonads
being an immunologically protected site where persistence
for months after infection has been recognized.5,8 Further-
more, PCR positivity does not necessarily indicate the pres-
ence of infectious virus, but may simply indicate residual
nucleic acids being cleared. Cell culture results are very often
negative on PCR-positive specimens.8,9
The epidemic has continued to accelerate dramatically in
West Africa. Many areas of Liberia and Sierra Leone have
passed tipping points in which ETUs can no longer accom-
modate the case load and measures are being implemented
for community-based management. Bed capacity has reached
a critical level in some areas. Novel but evidence-based strate-
gies are desperately needed to streamline operations to meet
this challenge. To reduce the community “viral load” and
optimize use of limited bed and laboratory capacity, we rec-
ommend that convalescent patients should be discharged if
asymptomatic for 48 hours and independently mobile, with
appropriate counseling regarding possible infection risk and
a basic discharge kit for infection control. This approach will
have the additional benefit of enabling already constrained
EVD testing laboratories to focus primarily on testing of
new cases, thereby increasing the rate at which EVD PCR-
negative suspect cases are identified and discharged, reducing
the risk of ward-based EVD transmission to these individuals
and freeing up additional beds. More conservative policies
requiring blood or even urine to be reverse transcription-PCR
(RT-PCR) negative before discharge may be maintained in
centers and laboratories where capacity remains sufficient to
perform such testing without unduly impacting the flow of
patients. In the longer term, research is needed to establish
evidence-based criteria and guidelines for safe discharge. This
research must include collection of a wide range of bodily
fluids from convalescent EVD patients and the testing of
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samples by both RT-PCR and, importantly, cell culture to
detect infectious virus.
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